News & Blogs » Peptide News » Scientists developed an innovative, label-free approach for visualizing whole-brain changes in Alzheimer’s disease
Alzheimer's disease is an chronic neurodegenerative disease affecting 5.5 million lives and their families in the US. To better study the pathological alterations during the progression of Alzheimer’s disease, researchers developed a new approach for imaging whole-brain changes in a mouse model of Alzheimer’s disease.
During disease progression, the brain will accumulate extracellular beta-amyloids in the grey matter, also known as senile plaques. Importantly, these senile plaques exhibit auto-fluorescence, especially after decreasing the tissue temperature to lower than -100 ⁰C. By utilizing this unique feature of the senile plaques, scientists developed a cryo-micro-optical sectioning tomography that is capable of imaging whole brain senile plaques in tissue samples immersed in liquid nitrogen without chemical labelling. This new system can provide more detailed information than traditional imaging techniques, including positron emission tomography (PET) or Magnetic resonance imaging (MRI), thus help deepen our understanding of the deterioration of brain function during the onset of Alzheimer's disease.
GenScript also synthesizes high quality peptide libraries for drug discovery, vaccine design, epitope mapping, and proteomics research.